MedTrace Logo

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

NCT02900560 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-06-10

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

CC-486

CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet

BIOLOGICAL

Pembrolizumab

Pembrolizumab 200 mg IV every 21 days

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Translational Research in Oncology

    lead OTHER

Principal Investigators

  • Rodrigo Fresco, MD · Translational Research in Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-20
Primary Completion
2021-05-27
Completion
2021-05-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02900560 on ClinicalTrials.gov